
## ALGORITHM FOR FORMULA SELECTION IN COWS' MILK PROTEIN ALLERGY (CMPA)<sup>1</sup>



#### FOR HEALTHCARE PROFESSIONALS ONLY

\* Stages 1 &2 only. \*\* Authorities for increased maximum quantities, up to a maximum of 20 may be authorised. # Authorities for increased maximum quantities, up to a maximum of 52 may be authorised. Patient must be 18 years of age or less.

FOS - Fructo-oligosaccharides MCT - Medium Chain Triglycerides CMPA - Cows' Milk Protein Allergy EOE - Eosinophilic Oesophagtis MFPA - Multiple Food Protein Allergy, TF - Total Fatty Acids. LCPs - Long Chain Polyunsaturated Fatty Acids scGOS - short chain galactooligosaccharides LFOS - long chain fructooligosaccharides. References: 1. Adapted from *Preece K et al*, NZMJ 2016; 129(1430)78-88 2. *Vanderhoof JA et al.* J Pediatr 1997; 131741-744 3. *De Boissieu D et al.* J Pediatr 1997; 131744-747 4. *Hill DJ et al.* J Pediatr 1999; 135118-121 5. ASCIA. Information for patients, consumers and careers. Cow's milk (dairy) allergy. Available at https://wwwallergy.org.au/patients/food-allergy/cows-milk-dairy-allergy. Accessed Nov 2020. 6. *Kemp AS et al.* MLA 2008;188(2):109-112. *T. Bach et al.* Am J Clin Nutr 1982; 36-950-962 8. *Giampietro PG et al.* Pediatr Allergy. Immnol 2001;12:83-6 9. *van der Aa, et al.* Clin Exp Allergy, 2010;40:795-804 10. ASCIA. Cow's milk (dairy) allergy. Available at https://wwwallergy.org.au/patients/food-allergy/cows-milk-dairy-allergy. Accessed October 2020. **11.** *Vanderhoof JA et al.* Intolerance to protein hydrolysate infant formulas. An underrecognized cause of gastrointestinal symptoms in infants. J Pediatr. 1997;131741-744. **12.** *de Boissieu D et al.* Allergy to extensively hydrolyzed cow milk proteins in infants. Identification and treatment with a minino acid-based formula. J Pediatr. 1997;131741-747. **13.** *et al.*, The natural history of intolerance to soy and extensively hydrolyzed cow milk proteins in infants. Identification and treatment with a minino acid-based formula. J Pediatr. 1997;131741-746. **16.** *Distory of the 2019*, **51.** *Harvey BM, et al.* Pediatr Res. 2014;75(2):343-351. **17.** *Birks AW, et al.* Pediatr. 1999;155:118-121. **14.** *Candy, et al.* Pediatr Allergy. Immonl. 2015;26(4):316-322.

**BREAST MILK IS BEST FOR BABIES.** Professional advice should be followed before using an infant milk formula. Social and financial implications should be considered when selecting a method of feeding. Please note that introducing partial bottle feeding could negatively affect breastfeeding. Good maternal nutrition is important for breastfeeding and reversing a decision not to breastfeed may be difficult. Infant formula should only be used as directed. Proper use of an infant formula is important for the infant.

Nutricia Australia Pty Ltd Talavera Corporate Centre Level 4 Building D, 12-24 Talavera Rd, Macquarie Park, NSW 2113. Nutricia Careline (Toll Free): 1800 438 500 www.nutricia.com.au/paediatrics/



# **NUTRICIA**



ALLERGY DIETARY MANAGEMENT & **PBS GUIDE** 

FOR HEALTHCARE PROFESSIONALS ONLY AUSTRALIA 2021

NUTRICIA'S UNIQUE SYNBIOTIC **BLEND CAN REBALANCE** THE GUT MICROBIOTA<sup>1-5</sup> **BRINGING IT CLOSER TO THAT OF HEALTHY BREASTFED INFANTS<sup>4</sup>** 



Specific prebiotic mixture scGOS/lcFOS or scFOS/lcFOS (9:1)

Specific probiotic mixture B. Breve M-16V

# Unique synbiotic blend



Aptamil<sup>®</sup> AllerPro Syneo contains -Bifidobacterium breve M-16V and scGOS/lcFOS (9:1), patented and clinically proven to modulate the gut microbiota similar to a breast fed infant.<sup>5</sup>



Neocate® Syneo contains -Bifidobacterium breve M-16V and scFOS/lcFOS (9:1) clinically proven to modulate the microbiota similar to a breastfed infant.<sup>8</sup>

# SYNEO IS PROVEN TO REBALANCE THE GUT MICROBIOTA<sup>1-5</sup> **BRINGING IT CLOSER TO THAT OF HEALTHY BREASTFED INFANTS<sup>4</sup>**

Hypoallergenic Safe and well tolerated Supporting normal growth in healthy infants and in infants with CMPA<sup>1-4</sup>



eHF with synbiotics scGOS/lcFOS/B.breve M-16V

AAF with synbiotics scFOS/lcFOS/B.breve M-16V

- Fewer experienced infections and lower % of infants requiring antibiotics<sup>1</sup>
- Fewer ear infection and use of anti-infectives<sup>2</sup> • Fewer infections and
- hospitalisations<sup>3</sup>

Harvey BM, et al. Pediatr Res. 2014;75(2):343–351. (AAF) 2 Burks AW, et al. Pediatr Allergy Immunol. 2015;26(4):316–322. (AAF) 3. PRESTO, unpublished data (AAF) 4. Abrahamse-Berkeveld M, et al.
J Nutr Sci. 2016;5:e42. (EHF) 5. Van Der Aa LB, et al. Clin Exp Allergy. 2010;(40):795–804. (EHF) 6. Candy, DCA, et al. Pediatric research, 2018;83(3):677–686. (AAF) 7. Fox AT, et al. Clin Transl Allergy. 2019;9(1):5. (AAF) 8. Michaelis LW, et al. Allergy, EAACI 2016;71(S102):93-4. 9. The Pharmaceutical Benefits Scheme, Accessed July 2018.



Rebalancing the gut microbiota composition, bringing it closer to that of healthy breastfed infants<sup>2,3,5-7</sup>



# Exploratory and safety outcomes show



#### Gastrointestinal

- Fewer infants with constipation and dry stools<sup>5</sup>
- Improved stool consistency and stool colour<sup>1,2</sup> closer to that of healthy breastfed infants
- Reduced need for medication for functional GI disorders<sup>2</sup>



Skin

- Effective resolution of skin symptoms in a subgroup of infants with IgE-mediated CMPA<sup>5</sup>
- Lower use of dermatological medication<sup>7</sup>



#### Asthma

• Lower prevalence of asthma-like symptoms and asthma medication at 1 year follow up<sup>5</sup>

### **NEOCATE® PBS ITEM NUMBERS<sup>9</sup>**



#### For infants/ children up to 24 months

Severe cows' milk protein enteropathy with failure to thrive					
Initial Treatment	11331J	5466Q	2246F	11161K	1180D
Continuing Treatment	11340W*	5467R*	2560R*	11183N*	1192R*
Cows' Milk Anaphalaxis					
Initial Treatment & Continuing Treatment	11340W*	5467R*	2560R*	11183N*	1192R*

#### For infants/ children up to 18 years

Eosinophilic Oesophagitis					
2 <sup>ND</sup> LINE	11343B#	1545H <sup>#</sup>	-	11161K* 11183N* (Cont.)	1521C#
2 <sup>ND</sup> LINE	Neocate <sup>®</sup> SYNEO™	Neocate® GOLD	Neocate® LCP	Neocate® Junior (Unflavoured)	Neocate® Junior (Vanilla)

#### For infants/ children up to 24 months

Cows' milk protein enteropathy with combined intolerance to soy protein and protein hydrolysate formulae					
Initial Treatment	11331J	5466Q	2246F	11161K	1180D
Continuing Treatment	11340W*	5467R*	2560R*	11183N*	1192R*
Proven combined IgE-mediated allergy to cows' milk protein and soy protein					
Initial Treatment	11331J	5466Q	2246F	11161K	1180D
Continuing Treatment	11340W*	5467R*	2560R*	11183N*	1192R*

#### In children over 24 months

Combined intolerance to cows' milk protein, soy protein and protein hydrolysate formulae					
Initial Treatment	11331J	5466Q	2246F	11161K	1180D
Continuing Treatment	11340W*	5467R*	2560R*	11183N*	1192R*

Severe intestinal malabsorption including short bowel syndrome					
Initial Treatment & Continuing Treatment	11340W*	5467R*	2560R*	11183N*	1192R*

To access more information on the prescription criteria for the above products go to www.pbs.gov.au/pbs/home

\* Authorities for increased maximum quantities, up to a maximum of 20 may be authorised. # Authorities for increased maximum quantities, up to a maximum of 52 may be authorised. Patient must be 18 years of age or less. IMPORTANT NOTICE: This is a prescription guide for Nutricia formula choices only. Not to be used as a diagnostic or medical algorithm. For detailed guidelines on the management of cows' milk protein allergy, please refer to Kemp et al, MJA, 2008; 188(2):109-112.

-best with Powder -best with Powder -best -bes		Province and the set of the set o	Proceeding of the second secon
eocate®	Neocate®	Neocate® Junior	Neocate® Junior
GOLD	LCP	(Unflavoured)	(Vanilla)

#### Other